Kindler appointed Pfizer chairman
Pfizer CEO Jeffrey Kindler replaces Hank McKinnell as chairman of the firm's board of directors, effective Dec. 19. The appointment is a vote of confidence in Kindler as the company looks to regain traction following the termination of development of its headline pipeline candidate torcetrapib/atorvastatin (1"The Pink Sheet" Dec. 11, 2006, p. 3). McKinnell, who resigned from the chief executive post in July, was slated to give up the chairman position in February 2007 (2"The Pink Sheet" Aug. 7, 2006, p. 3). Pfizer says McKinnell will step down from the board when he leaves the company in February...
You may also be interested in...
Pfizer will likely have to look to a constellation of smaller products, rather than a single large product, to replace Lipitor after the termination of the torcetrapib development program
Newly appointed CEO Jeffrey Kindler appears to be laying the groundwork for significant changes in Pfizer's strategic direction
As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.